Skip Navigation


Rheumatology Advance Access originally published online on July 15, 2008
Rheumatology 2008 47(9):1430-1431; doi:10.1093/rheumatology/ken240
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/9/1430    most recent
ken240v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kaul, A.
Right arrow Articles by Kiely, P. D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaul, A.
Right arrow Articles by Kiely, P. D. W.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTERS TO THE EDITOR

Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study

A. Kaul1, D. T. O’Reilly2, R. K. Slack2, D. Collins3, J. Walmsley4, O. Duke4 and P. D. W. Kiely1

1St George's Healthcare NHS Trust, London, 2West Suffolk Hospital, Bury St Edmonds, 3Great Western Hospital, Swindon and 4Epsom and St Helier NHS Trust, Epsom, UK

Correspondence to: A. Kaul, Department of Rheumatology, Royal Free Hospital, Pond Street, London NW3 2QG, UK. E-mail: arvind.kaul@royalfree.nhs.uk

The first 10% of the full text of this article appears below.

SIR, Combination DMARD therapy is increasingly used for the treatment of inflammatory arthritis because monotherapy often does not produce remission [1]. The contrasting modes of action of MTX and LEF make them attractive candidates for use in combination [2] with the potential to provide additive or synergistic actions, perhaps without the need for expensive biologic agents [3].

Although combination DMARDs in early RA confer long-term structural advantages [4,5], meta-analysis of clinical trial . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?